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Original article
Blood pressure (BP) measurement at conventional settings is 
still the primary method for evaluating hypertension in pri-
mary care. However, the number of patients self-monitoring 
their BP at home is increasing steadily.1,2 Home BP measure-
ment provides a large number of readings over a period of 
several days that are free from digit preference and the white-
coat effect, which translates into higher reproducibility and 
increased diagnostic accuracy compared with conventional 
measurement.3–6 In addition to its diagnostic benefits, home 
BP measurement is also highly acceptable to the patients and 
cost-effective.7–10 Because of these advantages over conven-
tional measurements, international and national guidelines 
currently recommend home BP monitoring for diagnosing 
and managing hypertension.11–13
Several studies have tried to define an optimal home meas-
urement schedule, mainly based on the statistical reproduc-
ibility of the readings over multiple days.14–17 Clinicians, 
however, make treatment decisions based on diagnostic 
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Background
Current guidelines make no outcome-based recommendations on the 
optimal measurement schedule for home blood pressure (BP).
METHodS
We enrolled 4,802 randomly recruited participants from three popu-
lations. The participants were classified by their (i) cross-classification 
according to office and home BP (normotension, masked hypertension, 
white-coat hypertension, and sustained hypertension) and (ii) home BP 
level (normal BP, high normal BP, grade 1 and 2 hypertension), while 
the number of home measurement days was increased from 1 to 7. The 
prognostic accuracy of home BP with an increasing number of home 
BP measurement days was also assessed by multivariable-adjusted Cox 
models.
rESuLTS
Agreement in classification between consecutive measurement 
days indicated near perfect agreement (κ ≥ 0.9) after the sixth 
measurement day for both office and home BP cross-classification 
(97.8% maintained classification, κ = 0.97) and home BP level (93.6% 
maintained classification, κ = 0.91). Over a follow-up of 8.3 years, 568 
participants experienced a cardiovascular event, and the first home 
BP measurement alone predicted events significantly (P ≤ 0.003). 
The confidence intervals (CIs) were too wide and overlapping to 
show superiority of multiple measurement days over the first meas-
urement day (hazard ratios per 10 mm Hg increase in systolic BP at 
initial day, 1.11 [CI 1.07–1.16]; that at 1–7 days, 1.18 [CI 1.12–1.24]). 
Masked hypertension, but not white-coat hypertension, was associ-
ated with increased cardiovascular risk, irrespective of the number 
of home measurement days.
concLuSIon
Even a single home BP measurement is a potent predictor of cardiovas-
cular events, whereas seven home measurement days may be needed 
to reliably diagnose hypertension.
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categories. To our knowledge, no previous study has evalu-
ated how an increasing number of home measurement days 
affects the reproducibility of the diagnostic BP categories. 
Furthermore, the few prognostic studies available have been 
performed in single populations and due to small sample 
size no subgroup analyses were possible.18,19 No outcome-
based recommendations therefore exist on how many days 
of self-measured home BP have been established.
The American Heart Association Scientific Statement 
on the Use and Reimbursement for Home Blood Pressure 
Monitoring1 states that 2–3 readings should be taken, both 
in the morning and at night, over a period of 1 week for a 
recommended total of ≥12 readings. The recent Japanese 
Society of Hypertension guidelines recommend that the mean 
of the values measured 5–7 days per week should be used.12 
The European Society of Hypertension Guidelines for Home 
Blood Pressure Monitoring20 also recommend 1-week’s home 
measurement, while the measurements recorded on the first 
day should be discarded. One reason for these inconsistent 
recommendations is that the majority of studies that have tried 
to define an optimal home measurement schedule were based 
on the reproducibility of the home-measured blood pressure 
instead of prognostic and cross-sectional clinical data.
The objective of our study was to determine how many 
days of home blood pressure measurement are needed to 
diagnose hypertension and to predict cardiovascular risk 
reliably.  We addressed these issues in 4,802 participants from 
three populations and enrolled in the International Database 
on HOme blood pressure in relation to Cardiovascular 
Outcomes (IDHOCO).21
METHodS
Study participants
IDHOCO consists of prospective studies conducted in the 
general population. All studies contributing to the IDHOCO 
database received ethical approval and have been described 
in detail in peer-reviewed publications.21 All participants 
gave informed written consent.
The IDHOCO21 database has been constructed using 
individual participants’ data including information on lon-
gitudinal follow-up of both fatal and nonfatal cardiovascular 
outcomes. Participants were recruited from Ohasama, Japan 
(n  =  2,777),4 Finland (Finn-Home; n  =  2,075),3 Tsurugaya, 
Japan (n  =  836),22,23 Montevideo, Uruguay (n  =  400),24 and 
Didima, Greece (n = 665).25 The Montevideo24 and Didima25 
participants were excluded from this analyses because of an 
insufficient number of home measurements (Montevideo, two 
measurements) or measurement days (Didima, three days).
Of the remaining 5,688 participants, we excluded 658 and 
228 participants because less than seven days of home meas-
urements or less than two conventional BP values were avail-
able, respectively.3,4,22,23 The number of participants available 
for the analysis therefore totaled 4,802.
BP measurements and classification
Conventional BP was measured with a standard mer-
cury sphygmomanometer or an automated device, using the 
appropriate cuff size, after the participants had rested for at 
least 2 minutes in the sitting or supine position.21 Participants 
measured their BP at home after at least 2 minutes of sitting 
rest with validated,21 oscillometric devices in the sitting posi-
tion. In the Finn-Home study, home BP was measured twice 
every morning and evening for seven consecutive days.3 In 
the Tsurugaya study, home BP was measured once every 
morning for up to 1 month.22,23 In the Ohasama study, home 
BP was measured once every morning and every evening for 
up to 1 month.4 The first morning home BP measurements 
on seven days were included in the analyses to obtain a uni-
form measurement schedule for all cohorts.
Based on the mean of two conventional measurements and 
the mean BP of 1–7 measurement days, participants were clas-
sified in four categories according to (i) the cross-classification 
based on conventional and home BP measurement (normo-
tension, white-coat hypertension, masked hypertension, and 
sustained hypertension) and (ii) home BP level (normal BP, 
high normal BP, grade 1 hypertension, and grade 2 hyperten-
sion). We defined white-coat hypertension as a conventional 
BP ≥140 mm Hg systolic or ≥90 mm Hg diastolic with a home 
BP <135 mm Hg systolic and <85 mm Hg diastolic.11–13 We 
defined masked hypertension as a conventional BP <140 mm 
Hg systolic and <90 mm Hg diastolic with a home BP ≥135 mm 
Hg systolic or ≥85 mm Hg diastolic.11–13 The remaining sub-
jects were classified as normotensive or sustained hyperten-
sive based on normality or elevation, respectively, of both 
conventional and home BPs. We also divided the partici-
pants into having normal BP (home BP <125 mm Hg systolic 
and <80 mm Hg diastolic), high normal BP (home BP 125–
135 mm Hg systolic and/or 80–85 mm Hg diastolic), grade 
1 hypertension (home BP 135–145 mm Hg systolic and/or 
85–90 mm Hg diastolic), and grade 2 hypertension (home BP 
≥145 mm Hg systolic and/or 90 mm Hg diastolic) according to 
previously published outcome-driven thresholds, which yield 
similar cardiovascular risks to the thresholds recommended 
by the Japanese and European Societies of Hypertension for 
conventional measurements.11,13,26
other measurements
In all cohorts, a questionnaire was used to obtain detailed 
information on each participant’s medical history, intake of 
medications, and smoking and drinking habits. We defined 
smoking as the current use of smoking materials. Body 
mass index was body weight in kilograms divided by height 
in meters squared. Serum total cholesterol and blood glu-
cose were determined by automated enzymatic methods on 
venous blood samples. Diabetes mellitus was a fasting or 
random blood glucose level of at least 7.0 or 11.1 mmol/l,21,27 
or the use of antidiabetic drugs.
ascertainment of events
We ascertained vital status and incidence of fatal and non-
fatal diseases from the appropriate sources in each country, as 
described in detail in a previous publication.21 The primary 
end point was a composite cardiovascular endpoint, includ-
ing cardiovascular mortality, nonfatal myocardial infarction, 
surgical and percutaneous coronary revascularization, heart 
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failure, and stroke. Secondary analyses were conducted on 
cardiovascular mortality and cerebrovascular events (fatal 
and nonfatal stroke not including transient ischemic attacks). 
Only the first cardiovascular event for each category during 
the study follow-up was accepted for analysis.
Statistical methods
For database management and statistical analysis, we 
used SAS software, version 9.3 (SAS Institute, Cary, NC). 
For comparison of means and proportions, we applied 
the large-sample Z test or analysis of variance and the χ2 
statistic, respectively. We used the kappa coefficient (κ) to 
assess the level of agreement between BP classifications 
based on the cumulative means of successive days of home 
measurement. Near perfect agreement was defined as κ ≥ 
0.9.28 We calculated incidence rates in each category, while 
standardizing by the direct method for sex and age (<40, 
40–59, and ≥60 years). To analyze the association between 
endpoints and the home BP, we used Cox models adjusted 
for cohort, sex, age, body mass index, smoking, history of 
cardiovascular disease, diabetes mellitus, treatment with 
antihypertensive drugs, and serum total cholesterol. We 
included home BP in the Cox models as the BP measured 
during one day, or the mean of a cumulatively increasing 
number of measurement days. In sensitivity analyses, we 
computed the differences in the hazard ratios between 
subgroups by introducing the appropriate interaction 
term in the Cox models. To determine the trend in the 
hazard ratios across the cumulative number of measure-
ment days, we used a design variable coded from 1 to 7 in 
single regression analysis.
rESuLTS
Table  1 lists the characteristics of the participants. The 
mean home BP on the first day was 4.0 mm Hg higher for 
systolic (95% confidence intervals [CI], 3.5–4.4; P < 0.0001) 
and 2.1 mm Hg higher for diastolic (CI 1.9–2.4; P < 0.0001) 
than BP measured on the last day.
BP cross-classification
We first examined how an increasing number of home 
measurement days modifies the classification into normo-
tension, and white-coat, masked, and sustained hyperten-
sion (Table 2). When the number of home BP measurement 
days increased from 1 to 7, the classification remained the 
same in 4,073 participants (84.8%). Agreement in classifica-
tion between consecutive measurement days indicated near 
perfect agreement (κ ≥ 0.9) already after the second meas-
urement day (93.5% maintained classification, κ = 0.90).
classification according to home BP level
Next, we examined how an increasing number of home 
measurement days modifies classification of the participants 
into normal BP, high normal BP, grade 1 hypertension, and 
grade 2 hypertension (Table 3). When the number of home 
BP measurement days was increased from 1 to 7, BP clas-
sification remained the same in 3,059 participants (63.7%). 
Agreement in classification between consecutive measure-
ment days indicated near perfect agreement (κ ≥ 0.9) after 
the sixth measurement day (93.6% maintained classification, 
κ = 0.91).
Table 1. Participants characteristics 
Characteristic Ohasama Finn-Home Tsurugaya Total
Number of participants 2,377 1,855 570 4,802
Age, y 60.1 ± 12.0 57.3 ± 8.6 75.1 ± 4.5 60.8 (11.5)
Sex, women 1,462 (61.5) 1,004 (54.1) 293 (51.4) 2,759 (57.5)
Body mass index, kg/m2 23.5 ± 3.1 27.4 ± 4.4 23.9 ± 3.3 25.2 (4.2)
Serum total cholesterol, mmol/l 5.0 ± 0.9 6.1 ± 1.1 5.2 ± 0.8 5.5 (1.1)
Current smoking 452 (19.0) 413 (22.3) 68 (11.9) 933 (19.4)
Diabetes mellitus 238 (10.0) 117 (6.3) 85 (14.9) 440 (9.2)
Previous cardiovascular disease 179 (7.5) 231 (12.5) 91 (16.0) 501 (10.4)
Antihypertensive drug treatment 481 (20.2) 422 (22.8) 234 (41.1) 1,137 (23.7)
Blood pressure, mm Hg
 1st day, systolic home 126.9 ± 18.3 133.1 ± 22.6 143.5 ± 21.8 131.3 ± 21.2
 1st day, diastolic home 76.2 ± 12.2 82.4 ± 11.7 78.6 ± 11.9 78.9 ± 12.3
 7th day, systolic home 124.5 ± 17.6 127.7 ± 21.1 137.7 ± 22.0 127.3 ± 20.0
 7th day, diastolic home 74.6 ± 12.1 79.8 ± 11.1 75.9 ± 11.0 76.7 ± 11.8
 Systolic conventional 131.3 ± 18.2 137.2 ± 20.0 144.3 ± 19.5 135.1 ± 19.6
 Diastolic conventional 74.5 ± 11.3 83.7 ± 10.5 83.0 ± 10.4 79.0 ± 11.8
Mean ± SD, % in parentheses. All of the analysis of variance and χ2 statistic P values for differences across the three cohorts were significant 
(P < 0.0001).
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cardiovascular prognosis
Median follow-up was 8.3  years (5th–95th percentile 
interval, 4.2–16.8). During 46,037 person-years of follow-up, 
568 participants experienced a fatal or nonfatal cardiovascu-
lar event (5.0 per 1,000 person-years), 221 died of cardiovas-
cular causes, and 337 suffered a cerebrovascular event. All 
individual and cumulative systolic (Figure 1, Supplementary 
Table S1; P < 0.0001) and diastolic (Supplementary Figure 
S1 and Table S1; P ≤ 0.01) BP measurements predicted the 
composite endpoint. When the home BP of the first meas-
urement day was included in the Cox model, the hazard 
ratios per 10-mm Hg increase in systolic and per 5-mm Hg 
increase in diastolic BP were 1.11 (CI 1.07–1.16) and 1.05 
(CI 1.02–1.09), respectively. The corresponding hazard 
ratios for the mean of seven measurement days were 1.18 
(CI 1.12–1.24) in systolic pressure and 1.10 (CI 1.06–1.15) 
in diastolic pressure. The P values for the linear trends were 
significant for systolic BP (P = 0.01), but not for diastolic BP 
(P = 0.17). However, the CIs were too wide and overlapping 
to show superiority of multiple measurements over a single 
measurement (Figure 1 and Supplementary Figure S1). No 
superiority of multiple over single days was observed even 
when the daily and cumulative mean BPs were calculated 
from all available measurements (one, two, and four meas-
urements per day in the Tsurugaya, Ohasama, and Finn-
Home cohorts, respectively; Supplementary Table S2).
Results were confirmatory when cerebrovascular events 
and cardiovascular mortality were used as the endpoint, 
although the hazard ratios of cardiovascular mortality in 
relation to diastolic BP were nonsignificant (Supplementary 
Table S3). Similar results were observed in subgroup analy-
ses according to antihypertensive treatment status, sex, and 
age (<60 vs. ≥60 years; Supplementary Tables S4, S5, and S6). 
Excluding one cohort at a time confirmed the main analyses 
of systolic BP, as reported in Supplementary Table S7.
Table 3. Classification of the participants according to the cumulative mean of home blood pressures measured on 1–7 days
Home measurement days
Blood  
pressure level 1 1–2 1–3 1–4 1–5 1–6 1–7
Normal blood 
pressure
1,655 1,775 (17.0) 1,851 (10.7) 1,887 (7.7) 1,934 (6.0) 1,955 (3.8) 1,990 (4.1)
Prehypertension 923 969 (47.6) 973 (32.0) 978 (23.3) 938 (16.9) 961 (15.1) 933 (10.9)
Grade 1 
hypertension
753 770 (51.2) 788 (34.3) 792 (22.7) 821 (20.5) 807 (14.4) 810 (11.4)
Grade 2 
hypertension
1,471 1,288 (9.0) 1,190 (5.8) 1,145 (5.1) 1,109 (4.5) 1,079 (3.6) 1,069 (3.1)
Maintained 
classification, %
73.5 82.3 87.3 89.7 92.2 93.6
Kappa coefficient 0.63 (0.62–0.65) 0.76 (0.74–0.77) 0.82 (0.81–0.84) 0.86 (0.85–0.87) 0.89 (0.88–0.90) 0.91 (0.90–0.92)
Table is reported as the number of participants in each blood pressure category (% of participants who were reclassified compared with the 
classification of the previous day). Kappa coefficient (95% confidence intervals) indicates agreement with the classification on the previous day.
Table 2. Cross-classification of participants according to conventional blood pressure and the cumulative mean of home blood pressures 
measured on 1–7 days
Home measurement days
Blood pressure 
cross-classification 1 1–2 1–3 1–4 1–5 1–6 1–7
Normotension 2,015 2,127 (9.4) 2,183 (5.1) 2,215 (3.0) 2,226 (2.1) 2,247 (2.1) 2,256 (1.5)
White-coat 
hypertension
563 617 (21.1) 641 (13.4) 650 (8.3) 646 (6.8) 669 (6.4) 667 (3.3)
Masked 
hypertension
835 723 (12.2) 667 (8.3) 635 (5.4) 624 (5.6) 603 (4.5) 594 (4.2)
Sustained 
hypertension
1,389 1,335 (5.7) 1,311 (4.7) 1,302 (3.5) 1,306 (3.7) 1,283 (1.6) 1,285 (1.9)
Maintained 
classification, %
89.7 93.5 95.9 96.4 97.1 97.8
Kappa coefficient 0.85 (0.84–0.86) 0.90 (0.89–0.91) 0.94 (0.93–0.95) 0.95 (0.94–0.95) 0.96 (0.95–0.96) 0.97 (0.96–0.97)
Table is reported as the number of participants in each blood pressure category (% of participants who were reclassified compared with the 
classification of the previous day). Kappa coefficient (95% confidence intervals) indicates agreement with the classification of the previous day.
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White-coat hypertension and cardiovascular events
Table 4 provides risk estimates for normotension, white-
coat hypertension, masked hypertension, and sustained 
hypertension when the classification was based on the mean 
BP of 1–7 measurement days. In a multivariable-adjusted 
Cox model, white-coat hypertension was not significantly 
associated with cardiovascular risk irrespective of the num-
ber of home measurement days (P ≥ 0.14).
In Table  4, the normotensive reference group varies 
depending on how many days of measurement the classifi-
cation is based on. In a further step of the analysis, we there-
fore applied the most stringent definition of normotension, 
which required that the conventional BP and all cumulative 
means of 1–7 home measurement days were within normal 
limits (Figure 2). The hazard ratios for white-coat hyperten-
sion vs. normotension were not statistically different (P ≥ 
0.27), ranging from 1.10 to 1.19. Conversely, applying the 
most stringent definition of hypertension (Supplementary 
Figure S2) showed that the risk of white-coat hypertension 
was consistently lower than that of sustained hypertension 
(P < 0.01) without any trend (P = 0.75).
Masked hypertension and cardiovascular events
In multivariable-adjusted analyses (Table  4), the risk 
associated with masked hypertension compared with nor-
motension was always significant (P ≤ 0.03) with estimates 
of excess risk ranging from 33% to 68%. Applying the most 
stringent definition of normotension (Figure 2) confirmed 
that the hazard ratios comparing masked hypertension 
with normotension were all significant (P < 0.03), ranging 
from 1.36 to 1.57, with a significant linear trend (P = 0.01). 
Conversely, applying the most stringent definition of hyper-
tension (Supplementary Figure S2) showed that the risk 
of masked hypertension was lower than that of sustained 
hypertension when first and 1–2 days home measurements 
were used (P ≤ 0.04), whereas the significance disappeared 
when 1–3 days or more home measurements were averaged 
(P ≥ 0.09). The P value for linear trend was also significant 
(P = 0.01).
dIScuSSIon
In this study, we examined how many home BP self-meas-
urement days are needed to diagnose hypertension and to 
predict cardiovascular risk reliably in an analysis of a com-
bined sample of individual participant data. The results show 
that no significant changes in classification for BP level or 
cross-classification according to home and conventional BP 
occur after the sixth day. The predictive power of home BP 
for cardiovascular events does not materially increase within 
the range of 1–7 measurement days and most of the predic-
tive power is obtained already on the first measurement day. 
Masked hypertension, but not white-coat hypertension, is 
associated with increased cardiovascular risk, irrespective of 
the number of home measurement days.
Several cross-sectional studies with selected cohorts of 
hypertensive patients have tried to assess the optimal num-
ber of home BP measurements. Chatellier et al.15 measured 
BP at home thrice in the morning and evening for 21 days 
in 79 hypertensive patients. They showed that 80% of the 
maximal reproducibility (reduction in the standard devia-
tion of differences between the average values of two home 
BP sessions) is obtained by averaging 15 measurements on 
the first 5 days.15 The Self-measurement for the Assessment 
of the Response to Trandolapril (SMART) study with 1,710 
hypertensive patients also showed that, after six home BP 
measurements, only a small improvement in reproduc-
ibility is achieved.17 Furthermore, two studies by Stergiou 
et al.14,16 demonstrated that in hypertensive patients, at least 
12 measurements taken on three days are needed for the 
reproducibility of home BP to be superior to that of conven-
tional measurements. However, correct BP classification, on 
which treatment decisions are usually based, plays a much 
more important role in clinical practice than the statistical 
reproducibility of measurements. Our results demonstrate 
that no significant changes in classification for BP level or 
cross-classification are observed after the sixth measurement 
day as approximately 95% of the participants maintain clas-
sification after this.
Instead of only cross-sectional analyses based on sta-
tistical reproducibility, the optimal schedule for home BP 
measurement should also be determined based on outcome 
data. Several prospective large-scale population and patient 
studies using home BP measurements with a wide variety of 
monitoring schedules have been conducted during the past 
two decades.3–5,25,29 Single measurements in the morning and 
evening were performed for up to 28 days in the Japanese 
Ohasama study,4 single morning and evening measurements 
were performed on one day in the Italian Pressioni Arteriose 
Monitorate e Loro Associazioni (PAMELA) study,29 dupli-
cate morning and evening measurements were collected 
during one week in the Finnish Finn-Home study,3 dupli-
cate morning and evening measurements during three days 
were performed in the Greek Didima study,25 and triplicate 
morning and evening measurements for four days were 
used in the French Self-Measurement of Blood Pressure 
at Home in the Elderly: Assessment and Follow-up study.5 
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Figure  1. Predictive values of systolic home blood pressures (BPs). 
Hazard ratios express the increase in cardiovascular event risk per 
10-mm  Hg elevation of systolic BP on cumulative days (1 to the indi-
cated times; filled square with dotted lines) and on individual days (open 
square) for cardiovascular events plotted on a log scale. Vertical lines rep-
resent 95% confidence intervals. 
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Despite such differences in monitoring schedules, these 
studies consistently showed strong prognostic value of home 
BP. Some of these studies have also demonstrated that only 
two home BP readings predict the risk of cardiovascular 
events.18,19,29,30 Our study demonstrates that even a single 
home BP measurement is a strong predictor of cardiovascu-
lar disease. In our study, as in previous studies, the prognos-
tic value of home BP within the range of 1–7 days increased 
only slightly and no significant differences in hazard ratios 
were observed.18,19 Increasing the number of measurements 
Table 4. Risk of cardiovascular endpoint by blood pressure cross-classification
Blood pressure 
cross-classification Number E/R Rate (SE) Hazard ratio (95% CI) P
Day 1
 Normotension 149/2,015 9.7 (0.8) 1.00
 White-coat hypertension 66/563 13.5 (1.6) 1.20 (0.89–1.60) 0.23
 Masked hypertension 121/835 14.8 (1.3) 1.33 (1.04–1.70) 0.025
 Sustained hypertension 232/1,389 19.0 (1.2) 1.64 (1.31–2.05) <0.0001
Days 1–2
 Normotension 158/2,127 9.6 (0.8) 1.00
 White-coat hypertension 70/617 13.0 (1.6) 1.16 (0.87–1.54) 0.32
 Masked hypertension 112/723 15.4 (1.5) 1.38 (1.07–1.77) 0.012
 Sustained hypertension 228/1,335 19.4 (1.3) 1.69 (1.35–2.11) <0.0001
Days 1–3
 Normotension 161/2,183 9.5 (0.8) 1.00
 White-coat hypertension 72/641 13.0 (1.5) 1.16 (0.88–1.54) 0.30
 Masked hypertension 109/667 16.2 (1.6) 1.44 (1.12–1.86) 0.005
 Sustained hypertension 226/1,311 19.5 (1.3) 1.73 (1.38–2.16) <0.0001
Days 1–4
 Normotension 161/2,215 9.3 (0.8) 1.00
 White-coat hypertension 72/650 13.2 (1.6) 1.20 (0.90–1.59) 0.22
  Masked hypertension 109/635 17.0 (1.6) 1.59 (1.24–2.05) 0.0003
 Sustained hypertension 226/1,302 19.4 (1.3) 1.80 (1.44–2.25) <0.0001
Days 1–5
 Normotension 162/2,226 9.3 (0.8) 1.00
 White-coat hypertension 68/646 12.6 (1.5) 1.16 (0.87–1.54) 0.32
 Masked hypertension 108/624 17.4 (1.7) 1.64 (1.28–2.12) 0.0001
 Sustained hypertension 230/1,306 19.8 (1.3) 1.84 (1.47–2.29) <0.0001
Days 1–6
 Normotension 167/2,247 9.4 (0.8) 1.00
 White-coat hypertension 75/669 13.5 (1.5) 1.23 (0.93–1.62) 0.14
 Masked hypertension 103/603 17.0 (1.7) 1.54 (1.19–1.98) 0.001
 Sustained hypertension 223/1,283 19.5 (1.3) 1.72 (1.38–2.15) <0.0001
Days 1–7
 Normotension 163/2,256 9.1 (0.7) 1.00
 White-coat hypertension 73/667 13.3 (1.6) 1.24 (0.93–1.64) 0.14
 Masked hypertension 107/594 18.0 (1.8) 1.68 (1.30–2.16) <0.0001
 Sustained hypertension 225/1,285 19.6 (1.3) 1.81 (1.45–2.26) <0.0001
Abbreviations: CI, confidence interval; SE, standard error.
Number E/R indicate the number of events/participants at risk. Definition of the blood pressure cross-classifications is given in the Methods. 
Rates (SE) of events per 1,000 person-year were standardized by the direct method for sex and age. Hazard ratios (95% confidence interval) 
express the risk compared with normotension and were adjusted for sex, age, body mass index, smoking, drinking, total cholesterol, diabetes, 
history of cardiovascular disease, and cohort.
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days from one adds only little to the predictive accuracy of 
the self-measured BP, but most likely also results in lower 
patient compliance and increased measurement errors.
Some previous studies have observed that the risk of car-
diovascular disease increases from normotension to white-
coat hypertension to masked hypertension to sustained 
hypertension.31,32 Our results show that masked hyperten-
sion carries an elevated cardiovascular risk, even when 
the diagnosis is based on the mean of one or seven home 
measurements. White-coat hypertension carried a cardio-
vascular risk comparable with normotension in our study, 
although with a larger study this difference could become 
statistically significant. Furthermore, the hazard ratios for 
masked hypertension showed an increasing trend when the 
diagnosis was based on an increasing number of measure-
ments, whereas the hazard ratios for white-coat hyperten-
sion remained the same. Our findings emphasize the need to 
recognize and actively treat masked hypertension although 
white-coat hypertensive individuals also need close follow-
up because nearly half of them have been shown progress to 
sustained hypertension during a eight-year follow-up.33
This study must be interpreted within the context of some 
potential limitations. Only the Finn-Home participants took 
their BP in duplicate in the morning and evening. We could 
not assess whether home BP should be measured twice, 
instead of once, at one measurement occasion. Therefore, the 
generalizability of the results to other procedures for home BP 
measurement is unknown. Furthermore, the original home 
monitoring schedules differed between studies, which might 
have affected the findings. Nevertheless, the current analysis 
of a combined sample is based on the individual participant 
data from unselected population cohorts. The external valid-
ity and generalizability of population-based results must be 
larger than those emerging from cohorts of selected hyperten-
sive patients, and the large sample size of IDHOCO enables 
us to provide sensitivity analyses. Finally, although there was 
wide overlap in the CIs of the hazard ratios of the Cox models, 
this is not necessarily evidence of non-association. However, 
because of the strong correlation between BP values based on 
the mean of consecutive number of measurements, there is no 
perfect method for comparing these hazard ratios.
In conclusion, even a single home BP measurement is a 
potent predictor of cardiovascular events. Hypertension 
may be reliably diagnosed by using a mean of seven read-
ings performed during seven days as no significant reclassi-
fication occurs after day 6, although the differences between 
various measurement schedules limit the generalizability of 
our results. A  longer period of measurement could slightly 
increase diagnostic accuracy. Nevertheless, the clinical rel-
evance of adding more measurements needs to be carefully 
evaluated because the probability of lower compliance and 
errors in a generalized use increases at the same time. The pre-
sent information could inform future guidelines in creating a 
unified recommended scheme for home BP measurement.
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 Table S1. Hazard Ratios for Cardiovascular Events with an Increasing Number of Home Measurement Days. 
No. of Days 
Systolic Pressure   Diastolic Pressure  
Cumulative  Individual   Cumulative  Individual  
Day 1  1.11 (1.07–1.16)‡ 1.11 (1.07–1.16)‡  1.06 (1.02–1.09)* 1.06 (1.02–1.09)* 
Days 1–2  1.13 (1.08–1.18)‡ 1.11 (1.06–1.15)‡  1.08 (1.03–1.12)† 1.07 (1.03–1.11)† 
Days 1–3  1.14 (1.08–1.19)‡ 1.11 (1.06–1.16)‡  1.08 (1.04–1.12)† 1.06 (1.02–1.09)* 
Days 1–4  1.15 (1.09–1.20)‡ 1.13 (1.08–1.18)‡  1.08 (1.04–1.13)† 1.06 (1.02–1.10)* 
Days 1–5  1.16 (1.11–1.22)‡ 1.16 (1.11–1.21)‡  1.10 (1.05–1.14)‡ 1.11 (1.07–1.15)‡ 
Days 1–6  1.17 (1.12–1.23)‡ 1.15 (1.10–1.20)‡  1.10 (1.05–1.15)‡ 1.08 (1.04–1.12)‡ 
Days 1–7  1.18 (1.12–1.24)‡ 1.15 (1.11–1.20)‡  1.10 (1.06–1.15)‡ 1.08 (1.04–1.12)‡ 
Trend P  <0.0001  0.012   0.0003  0.17  
Hazard ratios (95% confidence intervals) reflect the risk associated with 10-mm Hg increase in systolic and 5-mm Hg increase in diastolic blood pressure. Hazard ratios were adjusted 
for sex, age, body mass index, smoking, history of cardiovascular disease, diabetes mellitus, treatment with antihypertensive drugs, serum total cholesterol, and cohort. Significance of 
the hazard ratios: * P<0.01; † P<0.001; and ‡ P<0.0001.  
 Table S2. Hazard Ratios for Cardiovascular Events with an Increasing Number of Home Measurement Days When All Measurements 
Performed in All Cohorts Were Included in the Analyses  
No. of Days 
Systolic Pressure   Diastolic Pressure  
Cumulative  Individual   Cumulative  Individual  
Day 1  1.15 (1.09–1.20)† 1.15 (1.09–1.20)†  1.08 (1.04–1.12)* 1.08 (1.04–1.12)* 
Days 1–2  1.17 (1.11–1.23)† 1.15 (1.09–1.20)†  1.10 (1.05–1.15)† 1.09 (1.05–1.14)† 
Days 1–3  1.18 (1.12–1.24)† 1.16 (1.10–1.21)†  1.11 (1.06–1.16)† 1.10 (1.05–1.14)† 
Days 1–4  1.19 (1.13–1.25)† 1.18 (1.12–1.24)†  1.12 (1.07–1.17)† 1.09 (1.05–1.14)† 
Days 1–5  1.21 (1.15–1.27)† 1.21 (1.15–1.27)†  1.13 (1.08–1.18)† 1.14 (1.09–1.19)† 
Days 1–6  1.22 (1.16–1.28)† 1.20 (1.15–1.26)†  1.13 (1.08–1.19)† 1.12 (1.07–1.16)† 
Days 1–7  1.23 (1.16–1.29)† 1.20 (1.14–1.26)†  1.14 (1.09–1.19)† 1.11 (1.06–1.15)† 
Trend P  <0.0001  0.005   0.0002  0.078  
The maximum number of measurements per day per cohort was 1 for Tsurugaya, 2 for Ohasama, and 4 for Finn-Home. Hazard ratios (95% confidence intervals) reflect the risk 
associated with 10-mm Hg increase in systolic and 5-mm Hg increase in diastolic blood pressure. Hazard ratios were adjusted for sex, age, body mass index, smoking, history of 
cardiovascular disease, diabetes mellitus, treatment with antihypertensive drugs, serum total cholesterol, and cohort. Significance of the hazard ratios: * P<0.001; and † P<0.0001.  
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Table S3. Hazard Ratios for Cerebrovascular Events and Cardiovascular Mortality with a Cumulatively Increasing Number of 
Measurement Days  
No. of Days 
Cerebrovascular Events (n=337)  Cardiovascular Mortality (n=221) 
Systolic Diastolic  Systolic Diastolic 
Day 1  1.16 (1.10–1.23)§ 1.09 (1.04–1.14)‡  1.10 (1.03–1.18)† 1.03 (0.98–1.09) 
Days 1–2  1.18 (1.11–1.26)§ 1.10 (1.05–1.16)‡  1.10 (1.02–1.18)* 1.06 (1.00–1.13) 
Days 1–3  1.20 (1.12–1.28)§ 1.11 (1.06–1.17)§  1.10 (1.02–1.19)* 1.06 (0.99–1.13) 
Days 1–4  1.22 (1.14–1.30)§ 1.12 (1.06–1.18)§  1.12 (1.03–1.21)† 1.05 (0.98–1.12) 
Days 1–5  1.23 (1.15–1.31)§ 1.13 (1.07–1.19)§  1.12 (1.04–1.22)† 1.05 (0.98–1.12) 
Days 1–6  1.24 (1.16–1.32)§ 1.13 (1.07–1.20)§  1.13 (1.04–1.22)† 1.03 (0.97–1.11) 
Days 1–7  1.25 (1.16–1.33)§ 1.14 (1.08–1.20)§  1.14 (1.05–1.24)† 1.03 (0.97–1.11) 
Hazard ratios (95% confidence intervals) reflect the risk associated with 10-mm Hg  increase in systolic and 5-mm Hg increase in diastolic blood pressure. Hazard ratios were adjusted 
for sex, age, body mass index, smoking, history of cardiovascular disease, diabetes mellitus, treatment with antihypertensive drugs, serum total cholesterol, and cohort. Significance of 
the hazard ratios: * P<0.05; † P<0.01; ‡ P<0.001; and § P<0.0001.
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Table S4. Sensitivity Analysis for Cardiovascular Events by Antihypertensive Treatment Status  
No. of Days 
Untreated (E/R=329/3665)  Treated (E/R=239/1137)  Interaction P  
Systolic Diastolic  Systolic Diastolic  Systolic Diastolic 
Day 1  1.14 (1.08–1.21)§ 1.05 (1.01–1.10)*  1.07 (1.01–1.15)* 1.06 (1.00–1.12)*  0.033  0.56  
Days 1–2  1.17 (1.10–1.24)§ 1.08 (1.03–1.14)†  1.08 (1.00–1.16) 1.06 (1.00–1.13)*  0.015  0.23  
Days 1–3  1.17 (1.10–1.24)§ 1.09 (1.03–1.14)†  1.09 (1.01–1.17)* 1.07 (1.00–1.14)*  0.023  0.27  
Days 1–4  1.17 (1.10–1.25)§ 1.09 (1.03–1.15)†  1.11 (1.03–1.20)† 1.07 (1.01–1.15)*  0.049  0.31  
Days 1–5  1.19 (1.12–1.27)§ 1.10 (1.04–1.16)‡  1.12 (1.04–1.22)† 1.09 (1.02–1.16)*  0.049  0.30  
Days 1–6  1.20 (1.12–1.28)§ 1.11 (1.05–1.17)‡  1.14 (1.05–1.23)† 1.09 (1.02–1.16)*  0.063  0.24  
Days 1–7  1.21 (1.13–1.29)§ 1.12 (1.05–1.18)‡  1.15 (1.06–1.24)‡ 1.09 (1.02–1.17)*  0.076  0.21  
E/R indicates the number of cardiovascular events/participants at risk.  Hazard ratios (95% confidence intervals) reflect the risk associated with 10-mm Hg  increase in systolic and 5-
mm Hg increase in diastolic blood pressure. Hazard ratios were adjusted for sex, age, body mass index, smoking, history of cardiovascular disease, diabetes mellitus, serum total 
cholesterol, and cohort. Significance of the hazard ratios: * P<0.05; † P<0.01; ‡ P<0.001; and § P<0.0001.
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Table S5. Sensitivity Analysis for Cardiovascular Events by Sex  
No. of Days 
Women (E/R=246/2759)  Men (E/R=322/2043)  Interaction P  
Systolic Diastolic  Systolic Diastolic  Systolic Diastolic 
Day 1  1.10 (1.03–1.17)† 1.06 (1.00–1.12)*  1.12 (1.06–1.18)‡ 1.05 (1.00–1.10)*  0.97  0.75  
Days 1–2  1.11 (1.03–1.19)† 1.09 (1.03–1.16)†  1.14 (1.07–1.21)§ 1.07 (1.01–1.12)*  0.95  0.83  
Days 1–3  1.10 (1.02–1.19)* 1.09 (1.02–1.16)†  1.16 (1.09–1.23)§ 1.07 (1.02–1.13)*  0.73  0.72  
Days 1–4  1.12 (1.04–1.21)† 1.09 (1.03–1.17)†  1.16 (1.09–1.24)§ 1.07 (1.02–1.14)*  0.96   0.84  
Days 1–5  1.13 (1.04–1.22)† 1.11 (1.04–1.18)†  1.19 (1.11–1.27)§ 1.09 (1.03–1.15)†  0.79  0.84  
Days 1–6  1.14 (1.05–1.23)† 1.11 (1.04–1.19)†  1.20 (1.12–1.28)§ 1.09 (1.03–1.15)†  0.79  0.93  
Days 1–7  1.15 (1.06–1.24)‡ 1.12 (1.05–1.20)‡  1.20 (1.12–1.28)§ 1.09 (1.03–1.16)†  0.86  0.95  
E/R indicates the number of cardiovascular events/participants at risk.  Hazard ratios (95% confidence intervals) reflect the risk associated with 10-mm Hg  increase in systolic and 5-
mm Hg increase in diastolic blood pressure. Hazard ratios were adjusted for age, body mass index, smoking, history of cardiovascular disease, diabetes mellitus, treatment with 
antihypertensive drugs, serum total cholesterol, and cohort. Significance of the hazard ratios: * P<0.05; † P<0.01; ‡ P<0.001; and § P<0.0001.
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Table S6. Sensitivity Analysis for Cardiovascular Events by Age Group  
No. of Days 
<60 years (E/R=133/2307)  ≥60 years (E/R=435/2495)  Interaction P  
Systolic Diastolic  Systolic Diastolic  Systolic Diastolic 
Day 1  1.14 (1.03–1.25)* 1.06 (0.98–1.14)  1.10 (1.05–1.16)§ 1.05 (1.01–1.09)*  0.19  0.19  
Days 1–2  1.18 (1.06–1.31)† 1.07 (0.98–1.16)  1.11 (1.06–1.17)§ 1.08 (1.03–1.12)†  0.10  0.30  
Days 1–3  1.20 (1.07–1.33)† 1.07 (0.98–1.17)  1.12 (1.06–1.18)§ 1.08 (1.03–1.13)†  0.073  0.29  
Days 1–4  1.20 (1.07–1.34)† 1.08 (0.99–1.18)  1.13 (1.07–1.19)§ 1.08 (1.03–1.13)†  0.11  0.22  
Days 1–5  1.23 (1.09–1.37)‡ 1.10 (1.00–1.20)*  1.15 (1.08–1.21)§ 1.09 (1.04–1.15)‡  0.078  0.19  
Days 1–6  1.24 (1.11–1.40)‡ 1.11 (1.02–1.22)*  1.15 (1.09–1.22)§ 1.10 (1.04–1.15)‡  0.060  0.14  
Days 1–7  1.25 (1.12–1.41)‡ 1.12 (1.02–1.23)*  1.16 (1.10–1.23)§ 1.10 (1.05–1.15)‡  0.057  0.13  
E/R indicates the number of cardiovascular events/participants at risk.  Hazard ratios (95% confidence intervals) reflect the risk associated with 10-mm Hg  increase in systolic and 5-
mm Hg increase in diastolic blood pressure. Hazard ratios were adjusted for sex, age, body mass index, smoking, history of cardiovascular disease, diabetes mellitus, treatment with 
antihypertensive drugs, serum total cholesterol, and cohort. Significance of the hazard ratios: * P<0.05; † P<0.01; ‡ P<0.001; and § P<0.0001. 
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Table S7. Sensitivity Analysis in Systolic Blood Pressure for Cardiovascular Events with One Cohort Excluded  
No. of Days 
Ohasama Excluded  
(E/R=227/2425)  
 Finn-Home Excluded  
(E/R=390/2947)  
 Tsurugaya Excluded  
(E/R=519/4232)  
Cumulative  Individual   Cumulative  Individual   Cumulative  Individual  
Day 1  1.09 (1.02–1.15)* 1.09 (1.02–1.15)*  1.13 (1.07–1.19)‡ 1.13 (1.07–1.19)‡  1.12 (1.07–1.17)‡ 1.12 (1.07–1.17)‡ 
Days 1–2  1.12 (1.05–1.19)† 1.12 (1.05–1.19)†  1.13 (1.06–1.20)‡ 1.09 (1.03–1.16)*  1.14 (1.08–1.19)‡ 1.11 (1.06–1.16)‡ 
Days 1–3  1.12 (1.05–1.20)* 1.09 (1.02–1.16)*  1.14 (1.08–1.22)‡ 1.12 (1.06–1.18)‡  1.15 (1.09–1.20)‡ 1.11 (1.06–1.17)‡ 
Days 1–4  1.13 (1.05–1.21)† 1.12 (1.05–1.19)†  1.16 (1.09–1.23)‡ 1.14 (1.08–1.21)‡  1.15 (1.10–1.21)‡ 1.13 (1.08–1.18)‡ 
Days 1–5  1.15 (1.07–1.23)† 1.17 (1.10–1.25)‡  1.17 (1.10–1.25)‡ 1.15 (1.08–1.21)‡  1.17 (1.11–1.24)‡ 1.17 (1.12–1.23)‡ 
Days 1–6  1.16 (1.08–1.25)‡ 1.15 (1.08–1.23)‡  1.18 (1.10–1.26)‡ 1.14 (1.08–1.21)‡  1.18 (1.12–1.25)‡ 1.15 (1.10–1.21)‡ 
Days 1–7  1.17 (1.09–1.25)‡ 1.15 (1.08–1.22)‡  1.19 (1.11–1.27)‡ 1.15 (1.09–1.22)‡  1.19 (1.13–1.26)‡ 1.16 (1.11–1.22)‡ 
E/R indicates the number of cardiovascular events/participants at risk. Hazard ratios (95% confidence intervals) reflect the risk associated with 10-mm Hg increase in systolic blood 
pressure. Hazard ratios were adjusted for sex, age, body mass index, smoking, history of cardiovascular disease, diabetes mellitus, treatment with antihypertensive drugs, serum total 
cholesterol, and cohort. Significance of the hazard ratios: * P<0.01; † P<0.001; and ‡ P<0.0001.
- 9 - 
 
 
 
Figure S1. Predictive values of diastolic home blood pressures. Hazard ratios express the 
increase in cardiovascular event risk per 5 mm Hg elevation of diastolic blood pressure on 
cumulative days (1 to the indicated times; filled square with dotted lines) and on individual 
days (open square) for cardiovascular events plotted on a log scale.  Vertical lines 
represent 95% confidence intervals.   
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Figure S2. Risk of a cardiovascular endpoint associated with white-coat and masked hypertension vs. hypertension. In this analysis, 
hypertension was defined based on two conventional blood pressure readings and seven days of home blood pressure measurement, 
which required that the conventional blood pressure and all cumulative means of 1 to 7 home measurement days were elevated. 
Hazard ratios express the risk compared to hypertension and were adjusted for sex, age, body mass index, smoking, history of 
cardiovascular disease, diabetes mellitus, treatment with antihypertensive drugs, serum total cholesterol, and cohort.  Horizontal bars 
denote the 95% confidence interval of the hazard ratios.  White-coat hypertension was a conventional blood pressure ≥140/≥90 mm 
Hg and a home blood pressure <135/<85 mm Hg. Masked hypertension was a conventional blood pressure <140/<90 mm Hg and a 
home blood pressure ≥135/≥85 mm Hg. 
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Appendix 1. IDHOCO investigators.  
Japan (Ohasama): K. Asayama, T. Ohkubo, M. Kikuya, R. Inoue, M. Satoh, M. Hosaka, 
M.T. Utsugi, T. Hirose, A. Hara, N. Fukushima, T. Obara, H. Metoki, Y. Imai; Finland (Finn-
Home): T. Niiranen, J. Johansson, A. Jula; Japan (Tsurugaya): K. Ohmori-Matsuda, S. 
Kuriyama, M. Kakizaki, A. Hozawa, I. Tsuji; Greece (Didima): G. Stergiou, A. Kollias, G. 
Thomopoulou, P. Kalogeropoulos, I. Skeva, E. Nasothimiou, N. Pantazis, N. Baibas, T. 
Mountokalakis; Uruguay (Montevideo): J. Boggia, E. Sandoya; Belgium (Leuven): J.A. 
Staessen, L. Thijs, N. Cauwenberghs, Z. Zhang, F. Wei, J. Knez, A. Odili, Y. Gu, Y. Liu, Y. 
Jin, L. Jacobs, T. Kuznetzova. 
